Thursday, May 1st, 2025

China South Air Boosts International Capacity by 60.8%, Driving Strong Passenger Traffic Growth

Date: 17 September 2024
Broker Name: MIB Securities (Hong Kong) Ltd


August 2024 Operational Highlights

China South Air (1055 HK) showed solid growth in passenger capacity and traffic for August 2024. The airline’s passenger capacity increased by 12% year-on-year (YoY), showcasing its ongoing recovery and operational expansion.


Growth Across Different Routes

  • Domestic Routes: Passenger capacity rose by 2.3% YoY, while passenger traffic for domestic routes grew by 11.8%.
  • Regional Routes: Passenger capacity increased by 33.4% YoY, with passenger traffic for regional routes growing by 30.5%.
  • International Routes: The most substantial growth was seen in international routes, where passenger capacity surged by 60.8% YoY, and passenger traffic increased by 63.6%, indicating a significant recovery in global demand.

International Demand Recovery

China South Air’s international revenue passenger kilometers (RPK) reached approximately 84% of pre-Covid (2019) levels. Although slightly behind its peers, the airline made notable progress in restoring international capacity, with strong gains in passenger traffic.

KSH Holdings: Emerging Uptrend Signals Bullish Opportunity for Singapore Investors

Comprehensive Analysis of Stocks: KSH Holdings, Marco Polo Marine, and China Merchants Bank Comprehensive Analysis of Stocks: KSH Holdings, Marco Polo Marine, and China Merchants Bank Date: January 16, 2025 Broker: CGS-CIMB Securities KSH...

CapitaLand Ascott Trust Expands Portfolio with Strategic Acquisition of lyf Funan Singapore

Date: October 3, 2024Broker: Maybank Research Pte Ltd Overview of CapitaLand Ascott Trust (CLAS SP) CapitaLand Ascott Trust (CLAS SP) is a leading real estate investment trust (REIT) that invests in income-producing hospitality properties...

Innovent Biologics: Pharma Giant in the Making with Strong Growth Prospects

Company Highlights: Innovent Biologics is evolving from a biotech company to a major pharmaceutical player in China, driven by its diverse drug pipeline. Key drugs such as Sintilimab, the company’s leading anti-PD-1 antibody, and...